Article
Immunology
Jing Zhang, Hongguang Sheng, Xiaoyi Tang, Panpan Xia, Zhangwang Li, Minxuan Xu, Jianyong Ma, Yunfeng Shen, Peng Yu, Xiao Liu
Summary: According to a post-hoc analysis from the ORCHID trial, the use of non-steroidal anti-inflammatory drugs (NSAIDs) in hospitalized American adult COVID-19 patients is not associated with worse clinical outcomes, including 28-day mortality or hospital discharge. Furthermore, a meta-analysis of 14 studies involving 48,788 COVID-19 patients showed that NSAID use had a survival benefit and decreased the risk of severe COVID-19.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Immunology
Elise M. N. Ferre, Monica M. Schmitt, Sebastian Ochoa, Lindsey B. Rosen, Elana R. Shaw, Peter D. Burbelo, Jennifer L. Stoddard, Shakuntala Rampertaap, Tom DiMaggio, Jenna R. E. Bergerson, Sergio D. Rosenzweig, Luigi D. Notarangelo, Steven M. Holland, Michail S. Lionakis
Summary: Treatment with bamlanivimab and etesevimab in APECED patients may have potential benefits, as early administration can improve COVID-19 symptoms and prevent disease progression, without affecting the production of antibodies to the nucleocapsid protein of SARS-CoV-2.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Hojun Choi, Eui-Cheol Shin
Summary: COVID-19 patients with severe symptoms exhibit hyper-inflammatory responses, which contribute to disease progression. Anti-inflammatory therapies, such as corticosteroids, IL-6R inhibitors, and JAK inhibitors, have shown promising results in treating severe cases. Additionally, exosomes have been studied as novel therapeutic options for their anti-inflammatory properties.
Article
Medicine, Research & Experimental
Jordana Grazziela A. Coelho dos Reis, Geovane Marques Ferreira, Alice Aparecida Lourenco, Agata Lopes Ribeiro, Camila Pacheco da Silveira Martins da Mata, Patricia de Melo Oliveira, Daisymara Priscila de Almeida Marques, Linziane Lopes Ferreira, Felipe Alves Clarindo, Murillo Ferreira da Silva, Heitor Portella Povoas Filho, Nilson Roberto Ribeiro Oliveira, Maisah Meyhr D'Carmo Sodre, Sandra Rocha Gadelha, George Rego Albuquerque, Bianca Mendes Maciel, Ana Paula Melo Mariano, Mylene de Melo Silva, Renato Fontana, Lauro Juliano Marin, Renata Santiago Alberto Carlos, Amanda Teixeira Sampaio Lopes, Fabricio Barbosa Ferreira, Uener Ribeiro dos Santos, Iris Terezinha Santos de Santana, Hllytchaikra Ferraz Fehlberg, Rachel Passos Rezende, Joao Carlos T. Dias, Eduardo Gross, Gisele Assis Castro Goulart, Marie Gabriele Santiago, Ana Paula Motta Lavigne de Lemos, Aline O. da Conceicao, Carla Cristina Romano, Luciana Debortoli de Carvalho, Olindo Assis Martins Filho, Claudio Almeida Quadros, David L. Morris, Sarah J. Valle
Summary: This study evaluated the mucolytic and anti-inflammatory effects of BromAc (R) in tracheal aspirate samples from critically ill COVID-19 patients. The results showed that BromAc (R) had a significant mucolytic effect and reduced the action of cytokine storm, indicating its potential as a pharmacological treatment for COVID-19.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Infectious Diseases
Norberto Perico, Monica Cortinovis, Fredy Suter, Giuseppe Remuzzi
Summary: COVID-19 exhibits varying degrees of symptom severity, requiring different levels of care at different stages of the disease. Intervening early with anti-inflammatory drugs, especially NSAIDs, in the outpatient setting could prevent disease progression and long-term complications. Observational studies have shown promising results regarding the use of NSAIDs for early outpatient treatment of COVID-19.
LANCET INFECTIOUS DISEASES
(2023)
Review
Immunology
Wen Zhang, Chenman Qin, Yunyun Fei, Min Shen, Yangzhong Zhou, Yan Zhang, Xiaofeng Zeng, Shuyang Zhang
Summary: This article reviews the progress of anti-inflammatory and immune therapy in COVID-19, including different types of anti-inflammatory drugs, and discusses relevant clinical trials and real-world studies.
CLINICAL IMMUNOLOGY
(2022)
Review
Rheumatology
Aaron Z. Reyes, Kelly A. Hu, Jacob Teperman, Theresa L. Wampler Muskardin, Jean-Claude Tardif, Binita Shah, Michael H. Pillinger
Summary: The search for effective COVID-19 management strategies is ongoing, with colchicine showing promise in targeting multiple mechanisms associated with excessive inflammation. Outpatient treatment with colchicine could potentially reduce the need for hospitalization and mortality due to COVID-19, benefiting both resource-replete and resource-poor regions by reducing the demand for rare or expensive care resources.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Medicine, General & Internal
Vanesa Seery, Silvina C. Raiden, Silvia C. Algieri, A. Grisolia, Daniela Filippo, Norberto De Carli, Sandra Di Lalla, Hector Cairoli, Maria J. Chiolo, Claudia N. Meregalli, Lorena I. Gimenez, Gabriela Gregorio, Mariam Sarli, Ana L. Alcalde, Carolina Davenport, Maria J. Bruera, Nancy Simaz, Mariela F. Perez, Valeria Nivela, Carola Bayle, Patricia Tuccillo, Maria T. Agosta, Hernan Perez, Susana Villa Nova, Patricia Suarez, Eugenia M. Takata, Mariela Garcia, Jorge Lattner, Maria J. Rolon, Patricia Coll, Ines Sananez, Maria P. Holgado, Fernando Ferrero, Jorge Geffner, Lourdes Arruvito
Summary: Neutrophils in children with COVID-19 exhibit a unique phenotype with high expression of inhibitory receptors and low expression of adhesion molecules, potentially preventing tissue infiltration. The expression of CD64 and serum IgG antibodies to the spike protein of SARS-CoV-2 can differentiate asymptomatic cases from mild and moderate cases of COVID-19.
Review
Pharmacology & Pharmacy
Zhicheng Liu, Zhuolei Han, Xin Jin, Jusung An, Jaewon Kim, Wenting Chen, Jong Seung Kim, Ji Zheng, Jun Deng
Summary: The treatment of COVID-19 is still inadequate, and microenvironmental disorder plays a significant role in the progression of the disease in patients. Advances in nanomaterial technologies offer potential opportunities for restoring homeostasis and treating COVID-19.
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Pharmacology & Pharmacy
Xiaoxia Xie, Nana Zhang, Jingya Fu, Zhenzhi Wang, Zirun Ye, Zhijun Liu
Summary: Sleep disorders caused by COVID-19 have become a major concern, and Traditional Chinese Therapy (TCT) may be a potential therapeutic strategy by activating the cholinergic anti-inflammatory pathway to alleviate inflammation and associated symptoms.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Alice Courties, Jeremy Boussier, Jerome Hadjadj, Nader Yatim, Laura Barnabei, Helene Pere, David Veyer, Solen Kerneis, Nicolas Carlier, Frederic Pene, Frederic Rieux-Laucat, Bruno Charbit, Vincent Bondet, Darragh Duffy, Francis Berenbaum, Benjamin Terrier, Jeremie Sellam
Summary: The expression of cholinergic system members may be associated with COVID-19 severity and inflammatory response. The decreased expression of a negative dominant duplicate CHRFAM7A is correlated with COVID-19-induced hypercytokinemia.
SCIENTIFIC REPORTS
(2021)
Review
Pharmacology & Pharmacy
Dongling Liu, Xiang Zeng, Zufeng Ding, Fenghua Lv, Jawahar L. Mehta, Xianwei Wang
Summary: COVID-19 infection has a high mortality rate in patients with preexisting cardiovascular diseases, and those with cardiovascular comorbidities have a higher risk of death. Drugs used to treat COVID-19 can have adverse effects on the heart.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medical Laboratory Technology
Yichen Xiao, Jing Zhong, Jiahui Yang, Zhenyuan Fu, Bowen Wang, Lulu Peng, Xin Zuo, Xuan Zhao, Dalian He, Jin Yuan
Summary: This study investigates the efficiency and mechanism of myeloid-derived suppressor cells (MDSCs) in corneal alkali burns (CAB). The results demonstrate that MDSCs therapy significantly improves the development of CAB, downregulates the inflammatory pathway, and decreases the frequencies of macrophages and neutrophils. IL-10 is identified as the critical factor for MDSCs therapy.
TRANSLATIONAL RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Yewon Park, Joo Young Na, Joo-Youn Cho, Jaeseong Oh, Su-jin Rhee
Summary: Current understanding suggests that a cytokine storm plays a major role in COVID-19 mortality, leading to the proposal of anti-inflammatory therapeutics for severe patients. This study proposed a clinical trial design for the development of anti-inflammatory agents for COVID-19 treatment, considering the physiological and immunological processes of the disease.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Bin Li, Wei Wang, Weifeng Song, Zheng Zhao, Qingqin Tan, Zhaoyan Zhao, Lantian Tang, Tianchuan Zhu, Jialing Yin, Jun Bai, Xin Dong, Siyi Tan, Qunying Hu, Ben Zhong Tang, Xi Huang
Summary: The development of multifunctional alveolar macrophage-like nanoparticles (NPs) with photothermal inactivation capability provides a potential treatment strategy for COVID-19, offering combined antiviral and anti-inflammatory effects. In a mouse model of COVID-19, treatment with NIR-irradiated NPs decreases virus burden and cytokine levels, reduces lung damage and inflammation, and improves survival rates. This therapeutic approach may be applicable for early-stage COVID-19 treatment through atomization inhalation of NPs followed by NIR irradiation of the respiratory tract, reducing infection progression and transmission risk.